论文部分内容阅读
目的 检测载介孔二氧化硅纳米囊脂质体(MSN-LIPO)的弛豫特性,并探索其增强MRI T2加权成像的功能。方法 在体外条件下,应用MRI扫描仪对不同含铁浓度的MSN-LIPO进行MRI扫描,检测MSN-LIPO的弛豫特性。体内条件下,建立6只BALB/c裸鼠皮下恶性胶质瘤模型,随机分为2组,分别经瘤内和静脉注射同一浓度的MSN-LIPO。并在注射前、后行MRI扫描,对图像特征进行研究并对信号值进行统计学分析。结果 体外模型MRI成像显示,随着MSN-LIPO的浓度增高,图像信号强度逐渐降低;绘制弛豫率曲线,1/T_2和浓度在一定范围内具有良好的线性关系,测得弛豫率r_2=413.7 mmol~(-1)·s~(-1)。BALB/c裸鼠恶性胶质瘤模型MRI显示,瘤内注射MSN-LIPO后MRI信号强度值为15.34±1.24,低于注射前的211.44±5.34,差异有统计学意义(t=36.38,P<0.05);静脉注射MSN-LIPO后MRI信号强度值为179.00±4.35,低于注射前的235.99±5.17,差异有统计学意义(t=14.34,P<0.05)。结论 MSN-LIPO有良好的弛豫特性,在体内条件下有良好的MRI T_2加权肿瘤成像负性增强作用,有MRI T2加权成像造影剂功能。
Objective To investigate the relaxation properties of mesoporous silica nanoshells (MSN-LIPO) and to explore its function of enhancing MRI T2-weighted imaging. Methods The MRI-scanning of MSN-LIPO with different Fe concentrations was performed in vitro and the relaxation characteristics of MSN-LIPO were examined by MRI. In vivo, 6 BALB / c nude mice models of subcutaneous malignant glioma were established and randomly divided into 2 groups: the same concentration of MSN-LIPO was injected intratumorally and intravenously respectively. MRI scanning was performed before and after injection, and the image characteristics were studied and the signal values were statistically analyzed. Results In vitro MRI imaging showed that the intensity of the image decreased with the increase of the concentration of MSN-LIPO. The relaxation rate curve, 1 / T 2 and concentration had a good linear relationship within a certain range. The relaxation rate r 2 = 413.7 mmol -1 s -1. The MRI signal intensity of BALB / c nude mice model of malignant glioma showed that the signal intensity of MRI was 15.34 ± 1.24 after intratumoral injection of MSN-LIPO, which was lower than 211.44 ± 5.34 before injection (t = 36.38, P < 0.05). The signal intensity of MRI after intravenous injection of MSN-LIPO was 179.00 ± 4.35, which was lower than 235.99 ± 5.17 before injection. The difference was statistically significant (t = 14.34, P <0.05). Conclusion MSN-LIPO has good relaxation properties, good MRI T 2 -weighted tumor imaging negative enhancement in vivo, and MRI T2 weighted imaging contrast agent.